CGT Research Outlook and Technology Growth Opportunities

Description

CGT Landscape Assessment

The CGT landscape has evolved extensively over the past decade. More than 80 CGT products have been commercialized globally, with 34 FDA-approved cell and gene therapies in 2023 alone. The rise in product pipelines and clinical success rates has led to the growing demand for the development of new technology platforms, manufacturing capabilities, and expansion to new disease areas.

Over the past five years, the patent landscape, investment landscape, and clinical trial segment have had consistent growth and activity. All three segments contribute extensively to the growth of CGTs and showcase the promising potential of CGTs for the future. The CGT landscape has three main categories of therapies: cell therapies, gene therapies, and gene-modified cell therapies, with all three progressing well over the past years. Gene-modified cell therapies, such as CAR-T and CAR-NK, have a higher number of clinical programs in the pipeline and are expected to have a high clinical impact in the coming years.

CGT developers are exploring new disease areas, apart from hematological conditions and oncology, to include diabetes, cardiovascular diseases, and neurological conditions, which will boost the demand for CGTs.

The report covers the developments and trends in the CGT landscape. A collaborative environment showing the high adoption of new technologies to improve CGTs will transform the end-to-end capabilities in CGT development and manufacturing.

Patent activity is high because of consistent developments in technology for vector design, cell line manufacturing, digitalization of CGT manufacturing capabilities, and AI integration across the end-to-end CGT development. Venture capital firms see huge potential in the CGT segment in the coming years and have been constant supporters in backing start-ups and mid-sized CGT developers to accelerate their pipelines. In the coming years, the number of CGTs receiving regulatory approvals is predicted to multiply by three fold, and policies will be put in place to increase patient accessibility.

Product Code: DAE6

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Cell and Gene Therapy Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology

Growth Opportunity Analysis

Scope of Analysis
Segmentation

Growth Generator

Growth Drivers
Growth Restraints
Macro to Micro Visioning and Implications
Snapshot of CGT Development
Global Growth of CGT Approvals
CGT R&D Outlook
Manufacturing Expansion: Catalysts for CGT Manufacturing

CGT Patent Analysis

CGT-Overall Patent Trends
IP Landscape Gene-modified Cell Therapies
Top Patent Applicants in Gene-modified Cell Therapies
IP Landscape-Gene Therapies
Top Patent Applicants in Gene Therapies
IP Landscape Stem Cell Therapies
Top Patent Applicants in Stem Cell Therapies
An Overview of the Patent Landscape in CGTs

CGT Investment Landscape

Investment Trends in the CGT Landscape
Investment Trends in the CGT Expansion of Manufacturing Units
Investments in CGT Technology Platforms
Growing Mergers and Acquisitions
Early-stage CGT Investment Trends by Venture Capitalists
GV, United States
SAMSARA BIOCAPITAL, United States
ARCH VENTURE PARTNERS, United States
OrbiMed, United States
ALEXANDRIA, United States
RA CAPITAL, United States

CGT Publication Trend

Publication Trends in CGT

R&D Outlook across the Value Chain

Recent Initiatives and Research Accelerators Driving Innovations
Global Trends in CGT R&D
Emerging Technology Areas in CGT Development
Choice of Vector Depends on Indication and Transgene Expression
Engineering Viral Vectors to Improve Safety and Functionality
Innovations in Vector Engineering
Growing Shift from Autologous to Allogeneic Cell Therapies
Emerging Technology Trends for CGT Manufacturing
Shift toward Factory of the Future for CGT Manufacturing
Notable Recent Collaborations between CGT Platforms and Biopharma Companies to Accelerate CGT Development

CGT Clinical Trial Landscape

Clinical Pipeline Development of Gene Therapies
Clinical Development of Gene-modified Cell Therapies
Clinical Pipeline Development of Stem Cell Therapies

Growth Opportunity Universe in CGT

Growth Opportunity 1: Capacity and Capability Expansion for CDMOs
Growth Opportunity 2: Technology Licensing Partnerships
Growth Opportunity 2: Technology Licensing Partnerships
Growth Opportunity 3: Shift Towards CGT Development for Chronic Diseases

Appendix

Technology Readiness Levels (TRL): Explanation

Next Steps

Benefits and Impacts of Growth Opportunities
Next Steps
Take the Next Step
Legal Disclaimer